Last updated: July 1, 2026
Executive summary
Bausch Health Ireland Limited sued Mylan Laboratories Ltd. in the District of Delaware in January 2022 under the Hatch-Waxman framework, alleging Mylan’s abbreviated new drug application would infringe one or more patents listed for the branded reference product. The case tracks a typical Paragraph IV infringement track: pleadings, Markman-level patent claim construction steps, and dispositive motions, with the core business question tied to whether Mylan’s proposed product can enter before expiration of the asserted Orange Book patent(s).
Key actionable points
- Forum: U.S. District Court for the District of Delaware.
- Case number: 1:22-cv-00020.
- Parties: Bausch Health Ireland Limited (plaintiff) vs. Mylan Laboratories Ltd. (defendant).
- Procedural posture: Proceeded through the standard infringement litigation sequence for Hatch-Waxman disputes, including patent claim issues and motion practice.
- Business impact: Outcome affects launch timing and potential settlement or design-around strategy for Mylan.
What patents were asserted in Bausch Health Ireland v. Mylan (1:22-cv-00020)?
Answer (directional, litigation-driven): The infringement allegations are anchored to one or more patents listed in the Orange Book for the Bausch-branded reference product, and Mylan’s ANDA is the asserted launching vehicle.
What to look for in the docket
In this case type, the operative complaint and any amended complaint typically identify:
- asserted U.S. patents by number
- the Orange Book listing those patents correspond to
- the ANDA product (strength, dosage form)
- the infringement theories (literal infringement and/or doctrine of equivalents)
- the invalidity defenses (anticipation, obviousness, lack of enablement, indefiniteness)
- typical Hatch-Waxman hooks: 35 U.S.C. § 271(e)(2) infringement based on ANDA submission
Practical litigation analysis
- Plaintiff’s strongest early posture usually comes from claim construction clarity on the asserted claims’ construction-heavy limitations (chemical structure, formulation parameters, process steps, or method-of-use markers).
- Defendant’s strongest posture often comes from invalidity arguments that depend on the precise claim interpretation and the existence of clear prior art disclosures for each disputed limitation.
How does the court’s claim construction affect the infringement outcome?
Answer (case-type expectation): Claim construction is the decisive step that narrows infringement scope, determines whether the ANDA product “reads on” the asserted claims, and frames summary judgment risk.
Common claim-construction fault lines in Hatch-Waxman
- formulation patents: whether claimed parameters are numerical ranges that must be met exactly or interpreted broadly
- method-of-use patents: whether the ANDA labeling and intended use induce direct performance of the claimed steps
- composition-of-matter patents: whether the claimed species encompasses the generic formulation components and whether differences are structural or parameter-based
Impact on settlement economics
- Early adverse constructions tend to drive settlements because design-around becomes harder.
- Favorable constructions can increase defendant’s probability of summary judgment or favorable posture for trial.
When does BAUSCH Health’s Orange Book exclusivity end for this dispute?
Answer (directional): The exclusivity and patent-expiration timeline is the economic center of gravity for ANDA litigation. The case’s purpose is to establish whether Mylan can launch before the earliest of: expiration of the latest asserted patent, or any statutory exclusivity that blocks approval.
How exclusivity typically maps to litigation
- If the asserted patents are close to expiration, the practical leverage shifts to the likelihood of final judgment delaying launch.
- If expiration is far off, the litigation tends to incentivize earlier settlements tied to launch dates, carve-outs, and non-infringement/design-around commitments.
What is the Orange Book status of Bausch’s listed patents in this case?
Answer (directional): The asserted patents are Orange Book-listed and therefore attach to FDA approval timing. The Orange Book status informs both:
- statutory injury theory (271(e)(2))
- the “effective date” of infringement for damages purposes
- settlement triggers (licensed launch date or delayed approval)
Practical due diligence checklist for this specific docket
- confirm which patents were listed as expiring on the ORANGE BOOK listing for the reference drug
- confirm whether any patents are listed as method-of-use, formulation, or composition claims
- match each asserted patent to its specific expiration date
Was this a Paragraph IV challenge, and what does it mean for launch risk?
Answer (case-type expectation): The case is a Hatch-Waxman ANDA infringement suit consistent with a Paragraph IV challenge theory: Mylan submitted a certification that the listed patents are not infringed, invalid, or will not be infringed by the manufacture, use, sale, or importation of the proposed ANDA product.
Launch risk mechanics
- A Paragraph IV certification typically triggers:
- a potential 30-month stay (unless an exception applies)
- a stay ending when the statutory event happens (final court decision or settlement or resolution of regulatory event)
- If the court finds infringement and the patents do not expire first, generic launch is barred for the life of the patents.
What settlement or consent outcomes are likely in 1:22-cv-00020?
Answer (case-type expectation): Hatch-Waxman disputes of this profile often resolve via:
- stipulated dismissal after patent license,
- dismissal with prejudice after covenant-not-to-sue,
- or entry of a consent judgment tying launch to a date.
What materially changes the business outcome
- whether the settlement includes:
- a specific launch date
- carve-outs for non-asserted patents
- design-around permissions
- provisions on future litigation or patent additions.
What generic entry risks exist for Mylan after this litigation?
Answer (case-type expectation): If Mylan’s ANDA product was found infringing or if the court narrowed claim construction against the defendant, future entry risk rises. If invalidity arguments prevail or claim scope is narrowed to exclude Mylan’s product, entry risk decreases.
Key risk variables
- whether Mylan faces additional unasserted patents still listed for the reference product
- whether the reference holder brings additional continuations or newly asserted patents
- whether labeling carve-outs remain sufficient to avoid method-of-use exposure.
How strong is the patent estate for BAUSCH Health in similar ophthalmic or specialty portfolios?
Answer (portfolio pattern): Bausch Health typically holds patent estates spanning:
- composition and formulation (stability, particle properties, preservative systems)
- method-of-use (patient selection, dosing regimens)
- manufacturing and process improvements (scale and reproducibility).
What matters for litigation strength
- claim breadth and how many prior art references anticipate key limitations
- how courts construe parameter-based limitations
- whether asserted claims are vulnerable to obviousness combos
How does this case compare with other Bausch Health vs. generic defendants in Delaware?
Answer (comparative pattern):
- Delaware judges typically progress through:
- standard Markman scheduling
- dispositive motion practice after claim construction
- settlement at or after key rulings
- A defendant’s settlement leverage improves if:
- claim construction narrows disputed limitations
- prior art invalidity targets the center of the asserted claims
- the case sits near patent expiration or exclusivity boundaries
What is the procedural history for 1:22-cv-00020?
Answer (case-type expectation): The docket follows Hatch-Waxman staging:
- filing of complaint by Bausch
- responsive pleadings by Mylan
- claim construction briefing and hearing
- motion practice on infringement and invalidity
- possible settlement, dismissal, or trial scheduling
Business meaning of each step
- early-stage pleading disputes drive what patents and claims remain in play
- Markman is the major inflection point
- summary judgment decides the viability of either side’s core theory
Key takeaways
- The Bausch Health Ireland Limited v. Mylan Laboratories Ltd. litigation (D. Del., 1:22-cv-00020) is a Hatch-Waxman ANDA patent infringement dispute centered on Orange Book-listed patents.
- The commercial outcome depends on claim construction, infringement read-through of the ANDA product, and invalidity strength against the asserted limitations.
- The main business leverage comes from patent expiration proximity, whether settlement includes a defined launch date, and whether additional listed patents remain unasserted but still blocking approval.
FAQs
What is the typical relief sought in Hatch-Waxman suits like 1:22-cv-00020?
Infringement findings under 35 U.S.C. § 271(e)(2), injunctive relief preventing FDA approval/launch until patent expiration, and damages for pre-approval infringement.
Does an ANDA approval stay automatically apply after a Paragraph IV filing?
Typically yes, subject to statutory exceptions and events (for example, resolution dates or specific regulatory triggers).
How can claim construction change a case from infringement to non-infringement?
If key claim limitations narrow materially, the accused ANDA product may no longer meet the construed elements, creating grounds for non-infringement or limiting doctrine-of-equivalents arguments.
What settlement terms most affect generic launch timelines?
Defined launch dates, dismissal scope tied to asserted patents, covenants not to sue for remaining claims, and any permitted design-around that avoids future allegations.
What is the biggest invalidity risk for brand plaintiffs in such suits?
Prior art coverage that anticipates or renders obvious the specific limitations in the asserted claims, particularly once claim construction defines the precise scope.
References
- U.S. District Court for the District of Delaware, Bausch Health Ireland Limited v. Mylan Laboratories Ltd., No. 1:22-cv-00020 (docket and filings).
